SUMM.L

Summit Therapeutics Plc
Exercise of Restricted Stock Units
24th December 2019, 07:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Exercise of Restricted Stock Units

Summit Therapeutics plc 
(‘Summit’ or the ’Company’)

Exercise of Restricted Stock Units

Oxford, UK, and Cambridge, MA, US, 24 December 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces the exercise by Leopoldo Zambeletti, a Non-Executive Director of Summit, of restricted stock units (‘RSUs’) that entitled the holder to subscribe for an ordinary share of one penny nominal value at a subscription price of one penny per ordinary share. 

The RSUs were granted under the Company’s 2017 Remuneration Policy and were eligible for exercise for a limited time after completion of a vesting period of one year. Details of the exercise of the RSUs, all of which took place on 23 December 2019, and which have been duly notified to the Company, are summarised below.

DirectorPositionRSU’s ExercisedShareholding
(ordinary shares)		% of Issued Share Capital
Leopoldo ZambelettiNon-Executive Director17,07333,0520.02%

Application has been made to the London Stock Exchange for the admission of 17,073 ordinary shares to trading on AIM and it is expected that admission will become effective and that dealings will commence at 8.00 a.m. on or around 31 December 2019.

About Summit Therapeutics
Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for infections caused by C. difficile, N. gonorrhoeae and ESKAPE pathogens and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc.

Contacts

Summit  
Richard Pye (UK office)Tel:+44 (0)1235 443 951
Michelle Avery (US office) +1 617 225 4455
   
Cairn Financial Advisers LLP (Nominated Adviser)Tel:+44 (0)20 7213 0880
Liam Murray / Tony Rawlinson  
   



Notification of Transactions pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1Details of the persons discharging managerial responsibilities/person closely associated
a)Name (i)  Leopoldo Zambeletti
2Reason for the notification
a)Position / status (i)  Non-Executive Director
b)Initial notification / AmendmentInitial notification
3Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameSummit Therapeutics plc
b)LEI213800NRW8AOMYMTBD89
4Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentOrdinary shares of 1 penny each
  
Identification codeGB00BN40HZ01
b)Nature of the transactionsExercise of restricted stock units (RSUs) to subscribe for ordinary shares of one penny nominal value
c)Price(s) and volume(s) Price(s)Volume(s) 
(i) 1p (exercise price)

 		 (i)  17,073
 
d)Aggregated information

 

- Aggregated volume

 

- Price		 

 

17,073 ordinary shares

 

1 penny (exercise price)

 
e)Date of the transactions23 December 2019
f)Place of the transactionsOutside a trading venue

-END-

]]>

TwitterFacebookLinkedIn